FATE
Fate Therapeutics Inc
NASDAQ: FATE · HEALTHCARE · BIOTECHNOLOGY
$1.25
+0.81% today
Updated 2026-04-30
Market cap
$154.63M
P/E ratio
—
P/S ratio
23.27x
EPS (TTM)
$-1.15
Dividend yield
—
52W range
$1 – $2
Volume
1.4M
Fate Therapeutics Inc (FATE) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
7 of 8
Last 8 quarters
Avg EPS surprise
+10.5%
Last 4 quarters
Revenue YoY growth
-26.4%
Most recent quarter
EPS YoY growth
+38.6%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-7.4%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-7.4%
2026-03-02
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-02 | $-0.27 | +1.5% | $1.48 | $1.37 | -7.4% |
| 2025-11-13 | $-0.27 | +10.0% | $1.04 | $0.96 | -7.3% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.27 | $-0.27 | +1.5% | $1.37M | -26.4% |
| 2025-09-30 | $-0.30 | $-0.27 | +10.0% | $1.74M | -43.4% |
| 2025-06-30 | $-0.34 | $-0.29 | +14.7% | $1.91M | -71.8% |
| 2025-03-31 | $-0.38 | $-0.32 | +15.7% | $1.63M | -15.4% |
| 2024-12-31 | $-0.42 | $-0.44 | -3.8% | $1.86M | +11.0% |
| 2024-09-30 | $-0.41 | $-0.40 | +3.0% | $3.07M | +58.1% |
| 2024-06-30 | $-0.48 | $-0.33 | +31.2% | $6.77M | +625.8% |
| 2024-03-31 | $-0.49 | $-0.47 | +4.1% | $1.93M | -96.7% |
| 2023-12-31 | $-0.52 | $-0.45 | +13.5% | $1.68M | — |
| 2023-09-30 | $-0.57 | $-0.46 | +19.3% | $1.94M | — |
| 2023-06-30 | $-0.59 | $-0.54 | +8.5% | $933000.00 | — |
| 2023-03-31 | $-0.62 | $-0.19 | +69.4% | $58.98M | — |
| 2022-12-31 | $-0.86 | $-0.58 | +32.6% | — | — |
Frequently asked questions
Has Fate Therapeutics Inc beaten earnings estimates?
Fate Therapeutics Inc has beaten Wall Street EPS estimates in 7 of its last 8 quarterly reports, with an average EPS surprise of +10.5% over the last 4 quarters.
How does FATE stock react to earnings?
FATE stock has moved an average of -7.4% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is Fate Therapeutics Inc's revenue growth rate?
Fate Therapeutics Inc reported year-over-year revenue growth of -26.4% in its most recent quarter, with EPS growing +38.6% year-over-year.